Patents Examined by John Tarcza
  • Patent number: 4902618
    Abstract: A hybridoma continuous cell line, capable of producing monoclonal antibodies specific for all species of human interferon-alpha, is disclosed. A method for producing hybridomas and monoclonal antibodies with the required specificity is also disclosed. Methods of use of the disclosed compositions for purifying human interferon-alpha, screening blood in blood banks, and for producing specific polyclonal antibodies are claimed and detailed.
    Type: Grant
    Filed: March 14, 1986
    Date of Patent: February 20, 1990
    Assignee: Wadley Technologies, Inc.
    Inventor: Kurt F. Berg
  • Patent number: 4897466
    Abstract: A 6-thioguanine-resistant subvariant of the EBV-transformed human lymphoblastoid B cell line WI-L2 is described. The subvariant line, designated LTR228, fuses efficiently with human cells. Human.times.human hybridomas derived from LTR228 that produce monoclonal antibodies against tetanus toxin and blood group A are exemplified.
    Type: Grant
    Filed: June 6, 1986
    Date of Patent: January 30, 1990
    Assignee: Cetus Corporation
    Inventors: James W. Larrick, Andrew R. Raubitschek, Kenneth E. Truitt
  • Patent number: 4879222
    Abstract: A medium for the maintenance of mammalian anchorage-dependent colonic adenocarcinoma cells comprising a solution of an effective maintenance amount of buffered salts, L-glutamine and glucose, which is devoid of exogenous protein. The medium further includes a solution containing amino acids.
    Type: Grant
    Filed: August 28, 1986
    Date of Patent: November 7, 1989
    Assignee: President and Fellows of Harvard College
    Inventors: Edward M. Alderman, James W. Fett, Bert L. Vallee
  • Patent number: 4814272
    Abstract: Rhamnolipids with high surface activity are produced micro iologically in high yield per g of dry cell substance using Pseudomonas spec. DSM 2874 in the form of growing, resting and immobilized cell mass in an aqueous medium containing at least one assimilable carbon source at a pH of 6.7 to 7.3 and a temperature of to C. Two new rhamnolipids with only one .beta.-hydroxydecanoic acid residue in the molecule and defined as .alpha.-L-rhamnopyranosyl- and 2-O-.alpha.-L-rhamnopyranosyl-.alpha.-L-rhamnopyranosyl-.beta.-hydroxydeca noic acid with a molecular weight of 334 and 480, respectively, are obtained.
    Type: Grant
    Filed: February 15, 1985
    Date of Patent: March 21, 1989
    Assignee: Wintershall AG
    Inventors: Fritz Wagner, Christoph Syldatk, Uwe Matulowic, Hans-Jurgen Hofmann, Kai-Udo Sewe, Walter Lindorfer
  • Patent number: 4810646
    Abstract: Three dimensional glucan matrix compositions are prepared by separating growing Saccharomyces cerevisiae yeast from its growth medium, subjecting the yeast with cell walls intact to aqueous hydroxide and treating the insoluble glucan with acetic acid to alter the .beta.(1-6) linkages. The glucans have viscosity characteristics dependent upon the strain of Saccharomyces cerevisiae utilized and are useful as stabilizer or thickeners.
    Type: Grant
    Filed: November 28, 1984
    Date of Patent: March 7, 1989
    Assignee: Massachusetts Institute of Technology
    Inventors: Spiros Jamas, ChoKyun Rha, Anthony J. Sinskey
  • Patent number: 4804628
    Abstract: An improved cell culturing device includes a hollow fiber cartridge having a shell and a plurality of capillaries extending through the shell with at least some of the capillaries having selectively permeable walls. A cell culturing space is located between the shell and capillaries. The improvement includes a chamber containing a second medium supply fluidly connected to the cell culturing space. A pressurizing system pressurizes the medium within the chamber to a level higher than the level of medium flowing through the lumen of the capillaries. A valving mechanism alternatively and selectively restricts flow of medium between the chamber and the cell culturing space through first and second conduits such that circulation is effected in the cell culturing space.
    Type: Grant
    Filed: August 19, 1987
    Date of Patent: February 14, 1989
    Assignee: Endotronics, Inc.
    Inventors: Ray F. Cracauer, Robert D. Walker, Micheal L. Gruenberg
  • Patent number: 4798800
    Abstract: The present invention provides human characterized by a molecular weight of about 170,000 Dalton, a hexameric structure with monomeric subunits with a molecular weight of about 28,000 Dalton and a carbohydrate content of about 2%.The present invention provides a process for obtaining and purifying globular domain NC1 of basal membrane collagen, wherein human or animal tissue is subjected to a first limiting treatment with bacterial collagenase, the degradation products obtained are separated from non-collagen proteins by chromatography on a weakly basic anion exchanger, the collagen degradation products are then subjected to a second collagenase digestion at an elevated temperature and the globular domain NC1 is purified by molecular sieve fractionation.Furthermore, the present invention is concerned with the use of this for the determination in body fluids in the case of the use of their antibodies, as well as far the detection of antibodies directed thereagainst in body fluids.
    Type: Grant
    Filed: October 25, 1984
    Date of Patent: January 17, 1989
    Assignee: Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften e.V.
    Inventors: Rupert Timpl, Dietrich Brocks
  • Patent number: 4775632
    Abstract: Aqueous solutions of polysaccharide biopolymers, e.g., Xanthomonas/carbohydrate fermentation worts, are treated with mutanase-containing enzymes to improve the filterability and injectability thereof, and are well adapted, e.g., for secondary and tertiary hydrocarbon (petroleum) recovery by waterflooding therewith.
    Type: Grant
    Filed: August 30, 1984
    Date of Patent: October 4, 1988
    Assignee: Rhone-Poulenc Specialites Chimiques
    Inventors: Jean-Pierre Gozard, Alain Jarry, Alain Luccioni
  • Patent number: 4760021
    Abstract: There is provided a proteinaceous biological response modifier having the following properties: (a) molecular weight: 35,000 to 65,000; (b) isoelectric point: 5.0 to 6.1; (c) physiological action on human leukemia cells: to induce human leukemia to differentiate into macrophage-like cells; (d) physiological action on myeloid leukemia cells from mice: to induce myeloid leukemia cells from mice to differentiate into macrophage-like cells; (e) affinity to Concanavalin A Sepharose: not adsorbed; (f) affinity to Blue Sepharose Resin: not adsorbed; (g) pH-stability and thermostability: substantially not inactivated at pH 2 to 10, at C. for 6 hours; not inactivated at C. for 60 minutes; but inactivated by 30% at C. for 60 minutes; (h) sensitivity to enzymes: not inactivated by deoxyribonuclease; not inactivated by glycosidase; and inactivated by protease; (i) flow cytometry analysis: to concentrate cell division cycle of human leukemia cells to G.sub.0 /G.sub.1 phase.
    Type: Grant
    Filed: November 7, 1984
    Date of Patent: July 26, 1988
    Assignee: Director-General of Agency of Industrial Science & Technology
    Inventors: Akio Mimura, Kaoru Yoshinari, Katsumi Yuasa, Tsuneo Sato
  • Patent number: 4731328
    Abstract: This invention provides novel strains of microorganisms (e.g., Pseudomonas putida Biotype A) which are capable of converting substrates such as toluene or catechol to muconic acid quantitatively by the ortho (catechol 1,2-oxygenase) pathway.Muconate lactonizing enzyme is not induced in the microorganism, thereby permitting the muconic acid to be produced and accumulated in a quantity greater than one gram of muconic acid per liter of bioconversion medium.
    Type: Grant
    Filed: July 22, 1983
    Date of Patent: March 15, 1988
    Assignee: Celgene Corporation
    Inventor: Peter C. Maxwell
  • Patent number: 4729952
    Abstract: A process is disclosed for producing L-glutamic acid, the process involves culturing a microorganism belonging to the genus Corynebacterium or Brevibacterium and having both an ability to produce L-glutamic acid and a resistance to .alpha.-naphthoquinoline, an antibiotic inhibiting energy metabolism or a precursor for ubiquinone biosynthesis in a nutrient medium until L-glutamic acid is accumulated in the resulting culture liquor, and recovering the L-glutamic acid therefrom.
    Type: Grant
    Filed: February 23, 1984
    Date of Patent: March 8, 1988
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Kiyoji Hattori, Yukinobu Kotani, Kuniki Kino
  • Patent number: 4676981
    Abstract: A monoclonal antibody against GnRH and particularly designated USASK/DSIL-GnRH is produced by a hybrid formed by fusion of cells from a myeloma line and antibody producing cells of the immune system from an animal previously immunized with a source of GnRH; the monoclonal antibody has the following characteristics:(i) it produces a short term reduced means level of luteinizing hormone (LH) in immunized mammals;(ii) it produces a short term reduced pulsatile secretion of LH in immunized mammals;(iii) it terminates pregnancy in a female mammal with an accompanying decline in progesterone levels;(iv) it produces a long term reduced testosterone level in a male mammal, and(v) it induces infertility in a male mammal; thus passive immunization of the female or male with the monoclonal antibodies may be employed to reduce fertility and terminate pregnancy.
    Type: Grant
    Filed: February 7, 1984
    Date of Patent: June 30, 1987
    Assignee: University of Saskatchewan
    Inventors: David W. Silversides, Reuben J. Mapletoft, Bruce D. Murphy, Vikram Misra
  • Patent number: 4649115
    Abstract: Successive layers of guinea pig epidermis display discrete antigenic markers that are recognized by a selected panel of five monoclonal antibodies produced by hybridomas resulting from immunization of mice with suspensions of dissociated viable guinea pig epidermal cells. Antigen to Gpsk-1 marks the basement membrane, which membrane is probably produced by basal cells. Antigen to Gpsk-2 is expressed by basal and suprabasal cells. Antigens to both Gpsk-3 and Gpsk-4 occur on the spinous and overlying layers but are distinguished by differences in their representation on certain non-epidermal cell types and on other epithelia. Antigen to Gpsk-5 is found on basement membrane and on spinous and overlying granular and horny cells. Antigens to Gpsk-2 through 5 are situated at the cell surface and may recognize integral plasma membrane molecules expressed in differentiative sequence. The five antibodies differ also in their antigenic marker distribution among epithelial as well as other selected tissue types.
    Type: Grant
    Filed: March 31, 1983
    Date of Patent: March 10, 1987
    Assignee: Sloan-Kettering Institute
    Inventors: Bijan Safai, Edward A. Boyse, Fung-Win Shen
  • Patent number: 4603106
    Abstract: A mediator substance exhibiting inhibitory effect upon anabolic enzyme activity in mammals, is prepared by a method comprising gathering a sample of macrophage cells from a mammal, incubating a portion of the macrophage cells with a stimulating material that is associated with an invasive event, and inducing the macrophage cells to produce the mediator substance. The stimulator materials, for example, may include endotoxins, trypanosomes and the like, and the enzymes that may be observed range from lipoprotein lipase, acetyl Coenzyme A carboxylase and fatty acid synthetase, to the inducers for red blood cells growth and differentiation. The mediator substance may be utilized to raise antibodies which would in turn find utility in testing for the presence or amount of various invasive stimuli, such as infection and the like. Testing procedures and appropriate materials in kit form are also contemplated.
    Type: Grant
    Filed: September 7, 1982
    Date of Patent: July 29, 1986
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Masanobu Kawakami
  • Patent number: 4587217
    Abstract: A method is provided for the production of vicinal heterogeneous dihalogenated products from alkenes and alkynes. The alkene or alkyne is reacted in an aqueous solution of salts of two different halides, an oxidizing agent and an halogenating enzyme. Products provided by the method include novel 2,3-heterogeneously dihalogenated-1,4-butanediols.
    Type: Grant
    Filed: May 7, 1984
    Date of Patent: May 6, 1986
    Assignee: Cetus Corporation
    Inventors: John Geigert, Saul L. Neidleman
  • Patent number: 4544632
    Abstract: This invention provides a human parental T cell line which can fuse with normal human T cells, and hybrid cell lines which are prepared by fusion of the human parental T cells and the human T cells, and which are capable of producing lymphokines. This invention also provides methods of obtaining such human T cell lines, and a method of producing lymphokines from such hybrid cell lines.
    Type: Grant
    Filed: June 2, 1982
    Date of Patent: October 1, 1985
    Inventors: Yuichi Yamamura, Tadamitsu Kishimoto
  • Patent number: 4520107
    Abstract: This invention relates to a novel cell growth-promoting material for use as a supplement to basal tissue culture media for the cultivation of animal cells in vitro and to the method for its preparation. More particularly, it relates to an infusion consisting of growth-promoting material from adult, calf or fetal bovine blood clots as a supplement to basal media for cultivation of animal cells in vitro.
    Type: Grant
    Filed: September 28, 1982
    Date of Patent: May 28, 1985
    Assignee: Polydex Chemicals Ltd.
    Inventors: George M. Healy, Kenneth D. Curry
  • Patent number: 4486531
    Abstract: The present invention provides a process for the direct turbidimetric determination of .beta.-lipoproteins (LDL) in body fluids by precipitation with polyanions and divalent cations, wherein the precipitation is carried out in the presence of a complex former at a pH value of from 7 to 9.The present invention also provides a reagent for the direct turbidimetric determination of .beta.-lipoproteins (LDL) in body fluids, comprising a polyanion, a salt of a divalent metal, a complex former and a substance buffering at pH 7 to 9.
    Type: Grant
    Filed: May 4, 1983
    Date of Patent: December 4, 1984
    Assignee: Boehringer Mannheim GmbH
    Inventors: Joachim Ziegenhorn, Knut Bartl, Max Brandhuber
  • Patent number: 4455374
    Abstract: A solar fermentation process and distillation system for the manufacture of ethanol product suitable for blending with motor gasoline or as a substitute fuel for gasoline. Fermentation of starches or sugars is carried out in situ in solar collector tubes. The raw beer product emanating from the solar tubes is purified into a high quality ethanol fuel product by passing the beer product through a series of distillation columns whose internal reboil vapor is generated in whole or in substantial part through direct application of solar heat energy. The use of solar energy as heating source in the fermentation and distillation steps markedly reduces the need for external utilities such as steam and fuel to run the plant thereby greatly reducing the operating costs of the plant.
    Type: Grant
    Filed: July 14, 1982
    Date of Patent: June 19, 1984
    Inventor: David M. Schwartz
  • Patent number: 4452893
    Abstract: Fraction IV, a discard fraction of the Cohn fractionation scheme, may be used as a supplement in cell growth media if the Fraction IV is rendered substantially free of components within the molecular weight range 2.5.times.10.sup.5 -1.0.times.10.sup.10, which components inhibit cell growth.
    Type: Grant
    Filed: August 3, 1981
    Date of Patent: June 5, 1984
    Assignee: Cutter Laboratories, Inc.
    Inventors: Paul K. Ng, Milton B. Dobkin